GILD · News · 20261108N

HIV Prevention Persistence

GILEAD SCIENCES, INC. · 2026-11-08 · Importance 23 · Surprise 24

In the PURPOSE 5 trial, 85.6% of participants receiving twice-yearly injectable lenacapavir remained persistent through Week 52, compared with 46.3% receiving daily oral F/TDF for HIV prevention. The trial included individuals in the UK and France. No HIV acquisitions occurred in the lenacapavir group, and the persistence results suggest the twice-yearly option may help address adherence challenges in PrEP.

Key facts

• Gilead Sciences announced results from the PURPOSE 5 trial on twice-yearly injectable lenacapavir for HIV prevention. source
• Zero HIV acquisitions occurred in the lenacapavir group in the PURPOSE 5 trial. source
• In the PURPOSE 5 trial, 85.6% of lenacapavir recipients remained persistent through Week 52, versus 46.3% of those on daily oral F/TDF. source
• The PURPOSE 5 trial included individuals in the UK and France. source